

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-21 (Canceled)

22. (Previously Presented) A process for producing a cloned macrophage activating factor (GcMAFc) comprising:

- (a) cloning a Gc1 isoform into a baculovirus vector;
- (b) expressing the cloned Gc1 isoform, thereby producing a cloned Gc1 protein, wherein the Gc1 protein comprises approximately 458 amino acids with a molecular weight of approximately 52,000 Da and 3 distinct domains;
- (c) contacting the cloned Gc1 protein with immobilized beta galactosidase and sialidase; and
- (d) obtaining the cloned macrophage activating factor (GcMAFc).

Claim 23 (Canceled)

24. (New) A process for producing a functional cloned macrophage activating factor (GcMAFc) comprising:

- (a) cloning a Gc1 isoform into a baculovirus vector;
- (b) sequencing the cloned Gc1 isoform, thereby confirming that the cloned Gc1 isoform is a wild type Gc1 isoform;
- (c) expressing the sequenced wild type Gc1 isoform, thereby producing a cloned wild type Gc1 protein, wherein the cloned wild type Gc1 protein comprises approximately 458 amino acids with a molecular weight of approximately 52,000 Da and 3 distinct domains;
- (d) contacting the cloned wild type Gc1 protein in vitro with immobilized beta galactosidase and sialidase, and

Application No. 09/826,463

Reply to Notice of Non-Compliant Amendment Dated December 1, 2004

(e) obtaining the cloned wild type macrophage activating factor (GcMAFc).

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOW, LTD.

By _____

Robert S. Silver
Registration No. 35,681
Customer No. 03000
(215) 567-2010
Attorneys for Applicant

December 17, 2004

Please charge or credit our
Account No. 03-0075 as necessary
to effect entry and/or ensure
consideration of this submission.